GlassScriptPhysician profile
Rafael C Castro
NPI 1487604724
$1,188.38
in general payments reported to CMS, 2019-2025
27 companies · $21.86 in 2025
The $21.86 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $343 · 2020: $84.94 · 2022: $192 · 2023: $403 · 2024: $143 · 2025: $21.86.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $530 · Debt Forgiveness: $37.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $530.22 |
| Debt Forgiveness | $37.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $101.27 | 2019-2023 | |
| Novo Nordisk INC | $86.78 | 2019-2023 | Wegovy |
| Pfizer INC. | $79.60 | 2023-2024 | |
| Amgen INC. | $75.92 | 2019-2024 | Repatha, Otezla |
| Astellas Pharma US INC | $74.51 | 2019 | |
| Abbott Laboratories | $65.26 | 2022-2023 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $62.99 | 2019-2020 | |
| Glaxosmithkline, LLC. | $61.48 | 2022-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Daiichi Sankyo INC. | $58.36 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $54.11 | 2019-2023 | Farxiga |
| Reprise Biomedical, INC. | $53.21 | 2024-2025 | Miro3d |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.93 | 2020-2024 | Jardiance |
| Xeris Pharmaceuticals, INC. | $40.46 | 2023 | Gvoke Hypopen |
| Abbvie INC. | $39.01 | 2023 | Ubrelvy, Vraylar |
| Baxter Healthcare | $37.86 | 2023 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $37.24 | 2023-2024 | Inspire |
| Exact Sciences Corporation | $34.90 | 2023 | Cologuard Collection Kit |
| Horizon Therapeutics Plc | $28.75 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $24.73 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.49 | 2024 | |
| Genentech USA, INC. | $18.02 | 2019 | |
| Boston Scientific Corporation | $17.95 | 2019 | |
| Scilex Pharmaceuticals INC. | $17.18 | 2019 | |
| Shire North American Group INC | $14.42 | 2019 | |
| Lilly USA, LLC | $13.81 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.31 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $12.83 | 2023 | Camzyos |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rafael Castro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.